Session

IBD: Clinical trials poster II

BENEFIT OF PROLONGED FILGOTINIB DOSING IN PATIENTS WITH ULCERATIVE COLITIS WHO DID NOT RESPOND TO INDUCTION THERAPY: DATA FROM THE SELECTION LONG-TERM EXTENSION STUDY

Severine Vermeire, Alessandra Oortwijn, Simon Hatch, Silvio Danese, Toshifumi Hibi, Brian Feagan, William J. Sandborn

BENEFIT OF PROLONGED FILGOTINIB DOSING IN PATIENTS WITH ULCERATIVE COLITIS WHO DID NOT RESPOND TO INDUCTION THERAPY: DATA FROM THE SELECTION LONG-TERM EXTENSION STUDY

Severine Vermeire

BENEFIT OF PROLONGED FILGOTINIB DOSING IN PATIENTS WITH ULCERATIVE COLITIS WHO DID NOT RESPOND TO INDUCTION THERAPY: DATA FROM THE SELECTION LONG-TERM EXTENSION STUDY

Severine Vermeire

EFFECTIVENESS OF USTEKINUMAB DOSE ESCALATION IN CROHN'S DISEASE PATIENTS WITH INSUFFICIENT RESPONSE TO STANDARD-DOSE SUBCUTANEOUS MAINTENANCE THERAPY: AN OBSERVATIONAL MULTICENTRE STUDY

Raúl Olmedo-Martín

EFFECTIVENESS OF USTEKINUMAB DOSE ESCALATION IN CROHN’S DISEASE PATIENTS WITH INSUFFICIENT RESPONSE TO STANDARD-DOSE SUBCUTANEOUS MAINTENANCE THERAPY: AN OBSERVATIONAL MULTICENTRE STUDY

Raúl Olmedo-Martín, Laura Lorenzo-González, Marta Lázaro-Sáez, Federico Argüelles-Arias, Juan Maria Vázquez Morón, Manuel López-Vico, Alvaro Hernández Martínez, Maria Mar Martin Rodriguez

LONG-TERM OUTCOMES OF BIOLOGIC THERAPY IN CROHN'S DISEASE COMPLICATED WITH INTERNAL FISTULIZING DISEASE: BIOSCOPE STUDY FROM GETECCU

Iago Rodríguez-Lago

LONG-TERM OUTCOMES OF BIOLOGIC THERAPY IN CROHN’S DISEASE COMPLICATED WITH INTERNAL FISTULIZING DISEASE: BIOSCOPE STUDY FROM GETECCU

Iago Rodríguez-Lago, Francisco Mesonero, Fransisco Javier García-Alonso, Luisa de Castro, Beatriz Sicilia, Irene Gonzalez Partida, Leyanira Torrealba, Ainara Elorza, Elena Betoré, Fiorella Cañete, Xavier Calvet Calvo, Rocío Ferreiro-Iglesias, Sabino Riestra Menéndez, Pilar Varela Trastoy, Beatriz Castro Senosiain, Ana Gutier

LONG-TERM OUTCOMES OF BIOLOGIC THERAPY IN CROHN’S DISEASE COMPLICATED WITH INTERNAL FISTULIZING DISEASE: BIOSCOPE STUDY FROM GETECCU

Iago Rodríguez-Lago

PROACTIVE THERAPEUTIC DRUG MONITORING IS SUPERIOR TO STANDARD TREATMENT DURING MAINTENANCE THERAPY WITH INFLIXIMAB; THE RANDOMIZED NOR-DRUM PART B CLINICAL TRIAL

Kristin Kaasen Jørgensen

PROACTIVE THERAPEUTIC DRUG MONITORING IS SUPERIOR TO STANDARD TREATMENT DURING MAINTENANCE THERAPY WITH INFLIXIMAB; THE RANDOMIZED NOR-DRUM PART B CLINICAL TRIAL

Kristin Kaasen Jørgensen, Guro L Goll, Kristin H Bjørlykke, Silje W Syversen, Marthe K Brun, Øystein Sandanger, Joseph Sexton, Inge C Olsen, Johanna Gehin, David J. Warren, Rolf A Klaasen, Geir Noraberg, Carl M Ystrøm, Kathrine A Seeberg, Cato Mørk, Espen A Haavardsholm, Nils Bolstad, Jørgen Jahnsen, Tore K Kvien, Ingrid

PROACTIVE THERAPEUTIC DRUG MONITORING IS SUPERIOR TO STANDARD TREATMENT DURING MAINTENANCE THERAPY WITH INFLIXIMAB; THE RANDOMIZED NOR-DRUM PART B CLINICAL TRIAL

Kristin Kaasen Jørgensen

VEDOLIZUMAB AS FIRST-LINE BIOLOGICAL THERAPY IN ELDERLY PATIENTS AND THOSE WITH CONTRAINDICATIONS FOR ANTI-TNF THERAPY: A REAL-WORLD, NATIONWIDE COHORT OF PATIENTS WITH INFLAMMATORY BOWEL DISEASES

Camilla Höglund, Mohamed Attauabi, Janne Fassov, Kenneth Bo Pedersen, Heidi Bansholm Hansen, Signe Wildt, Anders Neumann, Michael Dam Jensen, Cecilie Lind, Henrik Albæk Jacobsen, Ana-Maria Popa, Akbar Molazahi, Kent Haderslev, Claus Aalykke, jens kjeldsen, Natalia Pedersen, Wojciech Cebula, Jakob Benedict Seidelin, Torben

VEDOLIZUMAB AS FIRST-LINE BIOLOGICAL THERAPY IN ELDERLY PATIENTS AND THOSE WITH CONTRAINDICATIONS FOR ANTI-TNF THERAPY: A REAL-WORLD, NATIONWIDE COHORT OF PATIENTS WITH INFLAMMATORY BOWEL DISEASES

Mohamed Attauabi

VEDOLIZUMAB THERAPEUTIC DRUG MONITORING AND REAL-WORLD OUTCOMES IN INFLAMMATORY BOWEL DISEASE

Waqqas Afif, John K. Marshall, Oksana Kaidanovich-Beilin, Ryan Ward, Cynthia Seow, Erin Stewart, Christopher Pettengell

VEDOLIZUMAB THERAPEUTIC DRUG MONITORING AND REAL-WORLD OUTCOMES IN INFLAMMATORY BOWEL DISEASE

Waqqas Afif

VEDOLIZUMAB THERAPEUTIC DRUG MONITORING AND REAL-WORLD OUTCOMES IN INFLAMMATORY BOWEL DISEASE

Waqqas Afif

Item 1 - 16 / 16
1